Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

@article{Shedden2008GeneES,
  title={Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study},
  author={Kerby Shedden and Jeremy MG Taylor and Steven A. Enkemann and Ming-Sound Tsao and Timothy Yeatman and William L. Gerald and Steven A. Eschrich and Igor Jurisica and Thomas J. Giordano and David E. Misek and Andrew C. Chang and Chang-Qi Zhu and D. Strumpf and Samir M. Hanash and Frances A. Shepherd and Keyue Ding and Lesley K Seymour and Katsuhiko Naoki and Nathan A. Pennell and Barbara A. Weir and Roel G. W. Verhaak and Christine Ladd-Acosta and Todd R. Golub and Mike Gruidl and Anupama Sharma and J{\'a}nos Szőke and Maureen F. Zakowski and Valerie Rusch and Mark G. Kris and Agnes J. Viale and Noriko Motoi and William D. Travis and Barbara A. Conley and Venkatraman E. Seshan and Matthew L Meyerson and Rork Kuick and Kevin K. Dobbin and Tracy G Lively and James W. Jacobson and David G. Beer},
  journal={Nature Medicine},
  year={2008},
  volume={14},
  pages={822-827}
}
Although prognostic gene expression signatures for survival in early-stage lung cancer have been proposed, for clinical application, it is critical to establish their performance across different subject populations and in different laboratories. Here we report a large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The hypotheses proposed examined whether microarray… Expand
Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
TLDR
In a large-scale evaluation, GEPs add prognostic value to standard clinicopathologic variables in lung adenocarcinoma, and are associated with patient outcome in both univariate and multivariate analyses, although not in all individual cohorts. Expand
Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma
TLDR
In inverse-variance weighting to combine the hazard ratios for the four datasets and pathway analysis to identify prognosis-associated gene signatures, a combined pathway-based risk (CPBR) score was derived that had more predictive power than single genes. Expand
Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
TLDR
The CCP score is a significant predictor of lung cancer death in early stage lung adenocarcinoma treated with surgery and may be a valuable tool in selecting patients for adjuvant treatment. Expand
A robust prognostic gene expression signature for early stage lung adenocarcinoma
TLDR
The new prognostic signature, if validated prospectively, may enable better stratification and treatment of early stage lung cancer patients and is strongly correlated with previously published signatures of chromosomal instability and cell cycle progression. Expand
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
  • H. Tang, S. Wang, +5 authors Y. Xie
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
TLDR
The goal of this study was to identify the most promising mRNA prognostic signatures in NSCLC for further prospective clinical validation and identify a set of mRNA expression prognostic signs appropriate for further validation in prospective clinical studies. Expand
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
TLDR
The gene signatures identified are promising tools for histo-pathological classification of non-small cell lung cancer, and may improve the prediction of clinical outcome. Expand
Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
TLDR
Little evidence is found that any of the reported gene expression signatures for non-small cell lung cancer are ready for clinical application and a set of guidelines are suggested to aid the design, analysis, and evaluation of prognostic signature studies. Expand
Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma
TLDR
Evidence for molecular basis of clinically relevant two distinct two subtypes of lung adenocarcinoma is provided, with integrated analysis of the signature revealed that E2F1 plays key roles in regulating genes in the signature. Expand
Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
TLDR
Using a novel NSCLC cohort together with a meta-analysis validation approach, a set of single genes with independent prognostic impact are identified and one of these genes, CADM1, was further established as an immunohistochemical marker with a potential application in clinical diagnostics. Expand
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients.
TLDR
The hypothesis that individual genetic characteristics, evidenced by the expression pattern of non-involved lung tissue, influence the outcome of lung adenocarcinoma patients' survival is supported. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Gene-expression profiles predict survival of patients with lung adenocarcinoma
TLDR
The identification of a set of genes that predict survival in early-stage lung adenocarcinoma allows delineation of a high-risk group that may benefit from adjuvant therapy. Expand
A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer
TLDR
A gene expression signature consisting of 64 genes that is highly predictive of which stage I lung cancer patients may benefit from more aggressive therapy is identified, useful in predicting survival of stage I NSCLC and might be useful in informing treatment decisions. Expand
A five-gene signature and clinical outcome in non-small-cell lung cancer.
TLDR
A five-gene signature that is closely associated with survival of patients with non-small-cell lung cancer is developed and validated with data from an independent cohort of 60 patients with NSCLC and with a set of published microarray data from 86 patients withNSCLC. Expand
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.
TLDR
Evidence is provided that molecular subtyping of NSCLC can identify distinct profiles of gene expression correlating with disease-free survival, and statistical analysis and clustering approaches were used to determine patterns of geneexpression segregating with clinical outcome. Expand
A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.
TLDR
The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC. Expand
RANTES expression is a predictor of survival in stage I lung adenocarcinoma.
  • C. Moran, D. Arenberg, +8 authors D. Beer
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
When tested in the Cox univariate proportional hazards model, RANTES expression by lung adenocarcinoma cells is a predictor of survival in stage I NSCLC patients and may be useful as a prognostic factor in lung cancer. Expand
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
TLDR
A molecular taxonomy of lung carcinoma is generated and results suggest that integration of expression profile data with clinical parameters could aid in diagnosis of lung cancer patients. Expand
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
TLDR
The state of the art of gene-expression studies in breast cancer is described, and the potential of molecular signatures to have an impact on individual breast cancer patient management, and ultimately to accelerate the transition between empirical and tailored medicine is discussed. Expand
Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer
  • Samuel J. Wang, C. Fuller, C. Thomas
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2007
TLDR
For patients with NSCLC surviving a period of time after diagnosis, 5-year CS rates vary by ethnicity, but African Americans continued to have lower CS rates compared with other ethnic groups, even up to 5 years from diagnosis. Expand
Diversity of gene expression in adenocarcinoma of the lung
TLDR
Gene expression analysis promises to extend and refine standard pathologic analysis and make possible the subclassification of adenocarcinoma into subgroups that correlated with the degree of tumor differentiation as well as patient survival. Expand
...
1
2
3
...